Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Jagoda Website

Elaine M. Jagoda, M.S.

Selected Publications

1)  Seidel J, Xi W, Kakareka JW, Pohida TJ, Jagoda EM, Green MV, Choyke PL.
Performance characteristics of a positron projection imager for mouse whole-body imaging.
Nucl. Med. Biol. 40: 321-30, 2013.
2)  Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P.
Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.
J. Nucl. Med. 53: 1592-600, 2012.
3)  Jagoda EM, Lang L, McCullough K, Contoreggi C, Kim BM, Ma Y, Rice KC, Szajek LP, Eckelman WC, Kiesewetter DO.
[(76) Br]BMK-152, a nonpeptide analogue, with high affinity and low nonspecific binding for the corticotropin-releasing factor type 1 receptor.
Synapse. 65: 910-8, 2011.
4)  Spinelli S, Chefer S, Carson RE, Jagoda E, Lang L, Heilig M, Barr CS, Suomi SJ, Higley JD, Stein EA.
Effects of early-life stress on serotonin(1A) receptors in juvenile Rhesus monkeys measured by positron emission tomography.
Biol. Psychiatry. 67: 1146-53, 2010.
5)  Bray M, Di Mascio M, de Kok-Mercado F, Mollura DJ, Jagoda E.
Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes.
Antiviral Res. 88: 129-42, 2010.
6)  Ma Y, Lang L, Reyes L, Tokugawa J, Jagoda EM, Kiesewetter DO.
Application of highly sensitive UPLC-MS to determine biodistribution at tracer doses: validation with the 5-HT1A ligand [(18)F]FPWAY.
Nucl. Med. Biol. 36: 389-93, 2009.
7)  Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J.
[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.
Eur. J. Nucl. Med. Mol. Imaging. 35: 1008-18, 2008.
8)  Dziegiel P, Dolilnska-Krajewska B, Dumanska M, Weclawek J, Jelen M, Podhorska-Okolow M, Jagoda E, Fic M, Zabel M.
Coexpression of CD1a, langerin and Birbeck's granules in Langerhans cell histiocytoses (LCH) in children: ultrastructural and immunocytochemical studies.
Folia Histochem Cytobiol. 45: 21-5, 2007.
9)  Kiesewetter DO, Jagoda EM, Shimoji K, Ma Y, Eckelman WC.
Evaluation of [18F]fluoroxanomeline {5-{4-[(6-[18F]fluorohexyl)oxy]-1,2,5-thiadiazol-3-yl}-1-methyl-1,2,3,6-tetrahydropyridine} in muscarinic knockout mice.
Nucl. Med. Biol. 34: 141-52, 2007.
10)  Dilsizian V, Eckelman WC, Loredo ML, Jagoda EM, Shirani J.
Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique.
J. Nucl. Med. 48: 182-7, 2007.
11)  Patel S, Hamill TG, Connolly B, Jagoda E, Li W, Gibson RE.
Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB.
Nucl. Med. Biol. 34: 1009-17, 2007.
12)  Martiniova L, Ohta S, Guion P, Schimel D, Lai EW, Klaunberg B, Jagoda E, Pacak K.
Anatomical and functional imaging of tumors in animal models: focus on pheochromocytoma.
Ann. N. Y. Acad. Sci. 1073: 392-404, 2006.
13)  Jagoda EM, Lang L, Tokugawa J, Simmons A, Ma Y, Contoreggi C, Kiesewetter D, Eckelman WC.
Development of 5-HT1A receptor radioligands to determine receptor density and changes in endogenous 5-HT.
Synapse. 59: 330-41, 2006.
14)  Ma Y, Lang L, Kiesewetter D, Jagoda E, Eckelman WC.
Species differences in metabolites of PET ligands: serotonergic 5-HT1A receptor antagonists 3-trans-FCWAY and 3-cis-FCWAY.
Nucl. Med. Biol. 33: 1013-9, 2006.
15)  Lang L, Jagoda E, Ma Y, Sassaman MB, Eckelman WC.
Synthesis and in vivo biodistribution of F-18 labeled 3-cis-, 3-trans-, 4-cis-, and 4-trans-fluorocyclohexane derivatives of WAY 100635.
Bioorg. Med. Chem. 14: 3737-48, 2006.
16)  Shirani J, Loredo ML, Eckelman WC, Jagoda EM, Dilsizian V.
Imaging the renin-angiotensin- aldosterone system in the heart.
Curr Heart Fail Rep. 2: 78-86, 2005.
17)  Jagoda EM, Vaquero JJ, Seidel J, Green MV, Eckelman WC.
Experiment assessment of mass effects in the rat: implications for small animal PET imaging.
Nucl. Med. Biol. 31: 771-9, 2004.
18)  Shimoji K, Ravasi L, Schmidt K, Soto-Montenegro ML, Esaki T, Seidel J, Jagoda E, Sokoloff L, Green MV, Eckelman WC.
Measurement of cerebral glucose metabolic rates in the anesthetized rat by dynamic scanning with 18F-FDG, the ATLAS small animal PET scanner, and arterial blood sampling.
J. Nucl. Med. 45: 665-72, 2004.
19)  Ciesielska U, Dziegiel P, Jagoda E, Podhorska-Okołów M, Zabel M.
The detection of Helicobacter pylori in paraffin sections using the PCR technique and various primers as compared to histological techniques.
Folia Morphol. (Warsz). 63: 229-31, 2004.
20)  Jagoda E, Contoreggi C, Lee MJ, Kao CH, Szajek LP, Listwak S, Gold P, Chrousos G, Greiner E, Kim BM, Jacobson AE, Rice KC, Eckelman W.
Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2.
J. Med. Chem. 46: 3559-62, 2003.
21)  Kiesewetter DO, Jagoda EM, Kao CH, Ma Y, Ravasi L, Shimoji K, Szajek LP, Eckelman WC.
Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation.
Nucl. Med. Biol. 30: 11-24, 2003.
22)  Shimoji K, Esaki T, Itoh Y, Ravasi L, Cook M, Jehle J, Jagoda EM, Kiesewetter DO, Schmidt K, Sokoloff L, Eckelman WC.
Inhibition of [18F]FP-TZTP binding by loading doses of muscarinic agonists P-TZTP or FP-TZTP in vivo is not due to agonist-induced reduction in cerebral blood flow.
Synapse. 50: 151-63, 2003.
23)  Jagoda EM, Kiesewetter DO, Shimoji K, Ravasi L, Yamada M, Gomeza J, Wess J, Eckelman WC.
Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice.
Neuropharmacology. 44: 653-61, 2003.
24)  Jagoda EM, Aloj L, Seidel J, Lang L, Moody TW, Green S, Caraco C, Daube-Witherspoon M, Green MV, Eckelman WC.
Comparison of an 18F labeled derivative of vasoactive intestinal peptide and 2-deoxy-2-[18F]fluoro-D-glucose in nude mice bearing breast cancer xenografts.
Mol Imaging Biol. 4: 369-79, 2002.
25)  Drag-Zalesińska M, Wysocka T, Dumańska M, Jagoda E, Zabel M.
Comparison of techniques permitting to detect apoptosis in situ.
Folia Histochem. Cytobiol. 40: 125-6, 2002.
26)  Kao CH, Waki A, Sassaman MB, Jagoda EM, Szajek LP, Ravasi L, Shimoji K, Eckelman WC.
Evaluation of [76Br]FBAU 3',5'-dibenzoate as a lipophilic prodrug for brain imaging.
Nucl. Med. Biol. 29: 527-35, 2002.
27)  Ma Y, Kiesewetter DO, Jagoda EM, Huang BX, Eckelman WC.
Identification of metabolites of fluorine-18-labeled M2 muscarinic receptor agonist, 3-(3-[(3-fluoropropyl)thio]-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine, produced by human and rat hepatocytes.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 766: 319-29, 2002.
28)  Zingone A, Seidel J, Aloj L, Caraco C, Vaquero JJ, Jagoda EM, Chou JY, Green MV, Eckelman WC.
Monitoring the correction of glycogen storage disease type 1a in a mouse model using [(18)F]FDG and a dedicated animal scanner.
Life Sci. 71: 1293-301, 2002.
29)  Kiesewetter DO, Jagoda EM, Starrett JE, Gribkoff VK, Hewawasam P, Srinivas N, Salazar D, Eckelman WC.
Radiochemical synthesis and biodistribution of a novel maxi-K potassium channel opener.
Nucl. Med. Biol. 29: 55-9, 2002.
30)  Ciesielska U, Jagoda E, Marciniak Z.
Value of PCR technique in detection of Helicobacter pylori in paraffin-embedded material.
Folia Histochem. Cytobiol. 40: 129-30, 2002.
31)  Green MV, Seidel J, Vaquero JJ, Jagoda E, Lee I, Eckelman WC.
High resolution PET, SPECT and projection imaging in small animals.
Comput Med Imaging Graph. 25: 79-86, 2001.
32)  Ma Y, Lang L, Kiesewetter DO, Jagoda E, Sassaman MB, Der M, Eckelman WC.
Liquid chromatography-tandem mass spectrometry identification of metabolites of two 5-HT1A antagonists, N-[2-[4-(2-methoxylphenyl)piperazino]ethyl]-N-(2-pyridyl) trans- and cis-4-fluorocyclohexanecarboxamide, produced by human and rat hepatocytes.
J. Chromatogr. B Biomed. Sci. Appl. 755: 47-56, 2001.
33)  Magata Y, Lang L, Kiesewetter DO, Jagoda EM, Channing MA, Eckelman WC.
Biologically stable [(18)F]-labeled benzylfluoride derivatives.
Nucl. Med. Biol. 27: 163-8, 2000.
34)  Lang L, Jagoda E, Schmall B, Sassaman M, Ma Y, Eckelman WC.
Fluoro analogs of WAY-100635 with varying pharmacokinetics properties.
Nucl. Med. Biol. 27: 457-62, 2000.
35)  Watabe H, Channing MA, Der MG, Adams HR, Jagoda E, Herscovitch P, Eckelman WC, Carson RE.
Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907.
J. Cereb. Blood Flow Metab. 20: 899-909, 2000.
36)  Carson RE, Lang L, Watabe H, Der MG, Adams HR, Jagoda E, Herscovitch P, Eckelman WC.
PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635.
Nucl. Med. Biol. 27: 493-7, 2000.
37)  Lang L, Jagoda E, Schmall B, Vuong BK, Adams HR, Nelson DL, Carson RE, Eckelman WC.
Development of fluorine-18-labeled 5-HT1A antagonists.
J. Med. Chem. 42: 1576-86, 1999.
38)  Aloj L, Caracó C, Jagoda E, Eckelman WC, Neumann RD.
Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture.
Cancer Res. 59: 4709-14, 1999.
39)  Kiesewetter DO, Carson RE, Jagoda EM, Herscovitch P, Eckelman WC.
In vivo muscarinic binding of 3-(alkylthio)-3-thiadiazolyl tetrahydropyridines.
Synapse. 31: 29-40, 1999.
40)  Kiesewetter DO, Carson RE, Jagoda EM, Herscovitch P, Eckelman WC.
Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands.
Life Sci. 64: 511-8, 1999.
41)  Ranganathan RS, Arunachalam T, Song B, Mantha S, Ogan M, Wedeking P, Yost F, Jagoda E, Tweedle M.
Evaluation of N,N'-bis-dimethyldiatrizoic acid analogs as liver imaging agents.
Acad Radiol. 5 Suppl 1: S23-7, 1998.
42)  Carson RE, Kiesewetter DO, Jagoda E, Der MG, Herscovitch P, Eckelman WC.
Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: control and competition studies.
J. Cereb. Blood Flow Metab. 18: 1130-42, 1998.
43)  Wu C, Jagoda E, Brechbiel M, Webber KO, Pastan I, Gansow O, Eckelman WC.
Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment.
Bioconjug. Chem. 8: 365-9, 1997.
44)  Lang L, Jagoda E, Wu C, Brechbiel MW, Gansow OA, Pastan I, Paik CH, Carrasquillo JA, Eckelman WC.
Factors influencing the in vivo pharmacokinetics of peptides and antibody fragments: the pharmacokinetics of two PET-labeled low molecular weight proteins.
Q J Nucl Med. 41: 53-61, 1997.
45)  Kiesewetter DO, Carson RE, Jagoda EM, Endres CJ, Der MG, Herscovitch P, Eckelman WC.
In vivo muscarinic binding selectivity of (R,S)- and (R,R)-[18F]-fluoromethyl QNB.
Bioorg. Med. Chem. 5: 1555-67, 1997.
46)  Lang L, Aloj L, Kiesewetter DO, Jagoda E, Lee JT, Paik CH, Carrasquillo JA, Eckelman WC.
A review of new oncotropic tracers for PET imaging.
Nucl. Med. Biol. 23: 669-72, 1996.
47)  Aloj L, Lang L, Jagoda E, Neumann RD, Eckelman WC.
Evaluation of human transferrin radiolabeled with N-succinimidyl 4-[fluorine-18](fluoromethyl) benzoate.
J. Nucl. Med. 37: 1408-12, 1996.
48)  Choi CW, Lang L, Lee JT, Webber KO, Yoo TM, Chang HK, Le N, Jagoda E, Paik CH, Pastan I.
Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts.
Cancer Res. 55: 5323-9, 1995.
49)  Jurisson SS, Pirro J, DiRocco RJ, Rosenspire KC, Jagoda E, Nanjappan P, Eckelman WC, Nowotnik DP, Nunn AD.
Boronic acid adducts of technetium dioxime (BATO) complexes derived from quinuclidine benzilate (QNB) boronic acid stereoisomers: syntheses and studies of their binding to the muscarinic acetylcholine receptor.
Nucl. Med. Biol. 22: 269-81, 1995.
50)  Zabel M, Surdyk-Zasada J, Lesisz I, Jagoda E, Wysocka T, Seidel J, Zabel-Olejnik J, Grzeszkowiak J.
Immunocytochemical studies on endocrine cells of alimentary tract of the pig in the embryonic and fetal period of life.
Folia Morphol. (Warsz). 54: 69-80, 1995.
51)  Jagoda EM, Wen ML, Yost FJ, Schreiber GJ, Tu JI.
An affinity column method for determination of the immunoreactivity of 131I-chimeric L6 monoclonal antibody and comparison to in vivo tumor localization.
J. Immunol. Methods. 173: 191-201, 1994.
52)  Zabel M, Surdyk-Zasada J, Lesisz I, Jagoda E, Wysocka T, Seidel J, Grzeszkowiak J.
Immunocytochemical studies on pancreatic endocrine cells at early stages of development of the pig.
Folia Histochem. Cytobiol. 32: 181-5, 1994.
53)  Ogan MD, Reiss AC, Croze EM, Jagoda EM, Stouffer BC, Mantha S, Tsay HM, Yost FJ, Tu JI.
A specific radioimmunoassay for the measurement of gadoteridol, a contrast agent for magnetic resonance imaging in biological fluids.
J Pharm Sci. 82: 475-9, 1993.
54)  Jagoda E, Stouffer B, Ogan M, Tsay HM, Turabi N, Mantha S, Yost F, Tu JI.
Radioimmunoassay for hydroxyphosphinyl-3-hydroxybutanoic acid (SQ 33,600), a hypocholesterolemia agent.
Ther Drug Monit. 15: 213-9, 1993.
55)  Jagoda E, Ogan M, Stouffer B, Tsay HM, Turabi N, Mantha S, Yost F, Tu JI.
A radioimmunoassay for the new antiviral agent 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Ther Drug Monit. 14: 499-508, 1992.
56)  Gibson RE, Moody T, Schneidau TA, Jagoda EM, Reba RC.
The in vitro dissociation kinetics of (R,R)-[125I]4IQNB is reflected in the in vivo washout of the radioligand from rat brain.
Life Sci. 50: 629-37, 1992.
57)  McManaway ME, Jagoda EM, Kasid A, Eckelman WC, Francis BE, Larson SM, Gibson RE, Reba RC, Lippman ME.
[125I]17-alpha-iodovinyl 11-beta-methoxyestradiol interaction in vivo with estrogen receptors in hormone-independent MCF-7 human breast cancer transfected with the v-rasH oncogene.
Cancer Res. 47: 2945-9, 1987.
58)  McManaway ME, Jagoda EM, Eckelman WC, Larson SM, Francis BE, Gibson RE, Reba RC, Lippman ME.
Binding characteristics and biological activity of 17 alpha-[125I]iodovinyl-11 beta-methoxyestradiol, an estrogen receptor-binding radiopharmaceutical, in human breast cancer cells (MCF-7).
Cancer Res. 46: 2386-9, 1986.
59)  Gibson RE, Eckelman WC, Reba RC, Jagoda EM, Rzeszotarski WJ, Grissom M, Conklin J, Eng R.
Receptor-selective localization in pancreas.
Int J Nucl Med Biol. 12: 29-32, 1985.
60)  Gibson RE, Rzeszotarski WJ, Jagoda EM, Francis BE, Reba RC, Eckelman WC.
[125I] 3-quinuclidinyl 4-iodobenzilate: a high affinity, high specific activity radioligand for the M1 and M2-acetylcholine receptors.
Life Sci. 34: 2287-96, 1984.
61)  Jagoda EM, Gibson RE, Goodgold H, Ferreira N, Francis BE, Reba RC, Rzeszotarski WJ, Eckelman WC.
[I-125] 17 alpha-Iodovinyl 11 beta-methoxyestradiol: in vivo and in vitro properties of a high-affinity estrogen-receptor radiopharmaceutical.
J. Nucl. Med. 25: 472-7, 1984.
62)  Gibson RE, Coenen HH, Jagoda E, Reba RC, Eckelman WC.
In vivo and in vitro characteristics of the N-methyl derivative of [125I]3-quinuclidinyl 4-iodobenzilate.
Int J Nucl Med Biol. 11: 167-9, 1984.
63)  Eckelman WC, Grissom M, Conklin J, Rzeszotarski WJ, Gibson RE, Francis BE, Jagoda EM, Eng R, Reba RC.
In vivo competition studies with analogues of 3-quinuclidinyl benzilate.
J Pharm Sci. 73: 529-34, 1984.
64)  Nakatsuka I, Ferreira NL, Eckelman WC, Francis BE, Rzeszotarski WJ, Gibson RE, Jagoda EM, Reba RC.
Synthesis and evaluation of (17 alpha,20E)-21-[125I]iodo-19-norpregna-1,3,5(10),20-tetraene-3,17 -diol and (17 alpha,20E)-21-[125I]iodo-11 beta-methoxy-19-norpregna-1,3,5(10),20-tetraene-3,17-diol (17 alpha-(iodovinyl)estradiol derivatives) as high specific activity potential radiopharmaceuticals.
J. Med. Chem. 27: 1287-91, 1984.
65)  Rzeszotarski WJ, Eckelman WC, Francis BE, Simms DA, Gibson RE, Jagoda EM, Grissom MP, Eng RR, Conklin JJ, Reba RC.
Synthesis and evaluation of radioiodinated derivatives of 1-azabicyclo[2.2.2]oct-3-yl alpha-hydroxy-alpha-(4-iodophenyl)-alpha- phenylacetate as potential radiopharmaceuticals.
J. Med. Chem. 27: 156-60, 1984.
66)  Gibson RE, Weckstein DJ, Jagoda EM, Rzeszotarski WJ, Reba RC, Eckelman WC.
The characteristics of I-125 4-IQNB and H-3 QNB in vivo and in vitro.
J. Nucl. Med. 25: 214-22, 1984.
67)  Rzeszotarski WJ, Gibson RE, Simms DA, Jagoda EM, Vaughan JN, Eckelman WC.
Cardioselectivity of beta-adrenoceptor blocking agents. 2. Role of the amino group substituent.
J. Med. Chem. 26: 644-8, 1983.
68)  Gibson RE, Rzeszotarski WJ, Eckelman WC, Jagoda EM, Weckstein DJ, Reba RC.
Differences in affinities of muscarinic acetylcholine receptor antagonists for brain and heart receptors.
Biochem. Pharmacol. 32: 1851-6, 1983.
69)  Rzeszotarski WJ, Gibson RE, Eckelman WC, Simms DA, Jagoda EM, Ferreira NL, Reba RC.
Analogues of 3-quinuclidinyl benzilate.
J. Med. Chem. 25: 1103-6, 1982.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/9/2014.